HUMA
Humacyte Inc

7,764
Mkt Cap
$219.11M
Volume
5.83M
52W High
$6.77
52W Low
$1.12
PE Ratio
-4.90
HUMA Fundamentals
Price
$1.12
Prev Close
$1.17
Open
$1.19
50D MA
$1.61
Beta
1.88
Avg. Volume
7.13M
EPS (Annual)
-$1.26
P/B
-39.12
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $11.00
Benchmark decreased their price objective on shares of Humacyte from $14.00 to $11.00 and set a "buy" rating for the company in a research note on Thursday...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Should You Invest in Humacyte, Inc. (HUMA) Based on Bullish Wall Street Views?
The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks·6d ago
News Placeholder
Humacyte (NASDAQ:HUMA) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS
Humacyte (NASDAQ:HUMA - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of...
MarketBeat·7d ago
News Placeholder
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +17.65% and -17.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
Humacyte, Inc. Q3 Loss Narrows
(RTTNews) - Humacyte, Inc. (HUMA) announced Loss for third quarter of -$17.51 million...
Nasdaq News: Markets·8d ago
News Placeholder
Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Humacyte in a research note on Monday...
MarketBeat·9d ago
News Placeholder
Insights Ahead: Humacyte's Quarterly Earnings
read more...
Benzinga·9d ago
News Placeholder
Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the company, Marketbeat.com...
MarketBeat·12d ago
News Placeholder
Humacyte (HUMA) to Release Quarterly Earnings on Friday
Humacyte (NASDAQ:HUMA) will be releasing its Q3 2025 earnings before the market opens on Friday, November 14. (View Earnings Report at...
MarketBeat·14d ago
News Placeholder
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.31, representing a -10% change from its previous close.
Zacks·14d ago

Latest HUMA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.